Veracyte
NASDAQ: VCYTSouth San Francisco, US · Incorporated in Delaware · 2 known investors
Find your way into Veracyte
307 people in our graph share verified history with the Veracyte team — schools, employers, funds. One of them is your warm intro.
Howardunlockedknows Julie Brooks · together at Santa Clara University School of Law
×4knows the team · via Georgetown Law
×7knows the team · via UW Foster School of Business
Veracyte develops genomic diagnostic tests for cancer, offering laboratory developed tests for thyroid, prostate, bladder, and breast cancers performed in its CLIA-certified, high-complexity labs. Its tests analyze each patient's tumor biology to help clinicians make personalized treatment decisions.
Founders & leadership
BH
Bonnie H. AndersoninFounder
JB
Julie BrooksinExecutiveShe has over 25 years of experience in legal, governance, IP, and M&A roles across medical technology, life sciences, and software companies, with expertise in corporate governance, SEC reporting, and international transactions.
SD
Shelly D. GuyerinExecutiveShelly D. Guyer is an executive with over 30 years of finance experience spanning venture capital and public markets, having held leadership roles at life sciences companies including iRhythm and Invitae, where she managed IPOs, equity and debt financings, and helped scale revenue from early stages to $450M. She also serves on multiple corporate and nonprofit boards.
MS
Marc StapleyinChief Executive OfficerMarc Stapley is Chief Executive Officer of Veracyte, a genomic diagnostics company that develops laboratory tests for cancer detection and treatment guidance. He brings experience across genomics, pharmaceuticals, telecommunications, software, and financial audit disciplines, and has served as a public company board member and audit committee chair.
Board
SD
Samuel D. ColellaBoard director
FE
Fred E. CohenBoard director
BG
Brian G. AtwoodBoard director
BH
JI
Jesse I. TreuBoard director
EJ
Evan JonesBoard director
KE
Karin EasthamBoard director
Investors · 2
Reported raises · per SEC filings
Form D private placements$12.8M disclosed across 1 round · 2014
▶$12.8MraisedSep 2014 · 6 investors · Other Health CareRule 506(b)
▶$12.8MraisedSep 2014 · 6 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Julie BrooksExecutive Officer
- Samuel D. ColellaDirector
- Shelly D. GuyerExecutive Officer
- Fred E. CohenDirector
- Brian G. AtwoodDirector
- Evan JonesDirector
- Brook H. ByersDirector
- Jesse I. TreuDirector
- Karin EasthamDirector
- Bonnie H. AndersonExecutive Officer, Director
- Offering amount
- $12.8M
- Amount sold
- $12.8M
- First sale
- Sep 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
How Investors May Respond To Veracyte (VCYT) Raising 2026 Revenue Guidance After Returning To Profit - Simply Wall St Newssimplywall.st · Aug 2026Veracyte (VCYT) Dropped, So What Is Behind The Latest Attention? - Simply Wall St Newssimplywall.st · Aug 2026
Veracyte posts 15% revenue surge in Q2, raises FY26 guidancescanx.trade · Jul 2026
Veracyte Q2 Earnings: $150M Revenue, Raises 2026 Guidance | VCYT Stock Newsstocktitan.net · Jul 2026Frequently asked questions
- What does Veracyte do?
- Veracyte develops genomic diagnostic tests for cancer, offering laboratory developed tests for thyroid, prostate, bladder, and breast cancers performed in its CLIA-certified, high-complexity labs. Its tests analyze each patient's tumor biology to help clinicians make personalized treatment decisions.
- Who founded Veracyte?
- Veracyte was founded by Bonnie H. Anderson.
- Who are Veracyte's investors?
- Veracyte's investors include Catalyst Health Ventures, Kleiner Perkins.
- How much funding has Veracyte raised?
- Veracyte has disclosed $12.8M raised across 1 round.
- Where is Veracyte headquartered?
- Veracyte is headquartered in South San Francisco, US.